Clinical Trial RisksRisks include clinical trial failures, insufficient efficacy, and inability to obtain timely approval of zanidatamab, which could negatively impact the stock.
Financial PerformanceZymeworks recorded a net loss of $0.31 per share, wider than the previously forecasted net loss of $0.12 per share, due to lower-than-expected revenue.
Market CompetitionFRa is a crowded target area, which could see overlap with other emerging targets like CDH6, posing a challenge to ZW191.